Black Diamond Therapeutics Inc

blackdiamondtherapeutics.com

What Do They Do?

Develops experimental targeted medicines for patients with genetically defined cancers, including non-small cell lung cancer and glioblastoma.

How Do They Make Money?

A partner pays for worldwide rights to develop and sell a drug candidate: Black Diamond received an upfront fee, may receive milestone payments if development or sales targets are reached, and royalties when the drug is sold.

FY2025 revenue

Who Are Their Customers?

Servier took a worldwide license to develop and sell a drug candidate, and leads its development and global sales.

Do Revenues Turn Into Profits?

Yes. It kept 32 cents of every revenue dollar as net income in FY2025.

Operating income, FY2025

18% of revenue

▲ Now profitable vs FY2024 (−$78.8M)

Net income, FY2025

32% of revenue

▲ Now profitable vs FY2024 (−$69.7M)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: vs $0 in Q2 FY2025
Net income: ▼ −6% (Loss); vs −$10.6M in Q2 FY2025

May 21, 2026 Trial reports updated silevertinib results The trial reported preliminary median progression-free survival of 15.2 months; the company said safety and efficacy data support 150 mg once daily for pivotal development.

Partner-led development The older report described a broad mutation-targeting candidate as a program the company planned to advance into clinical testing; the latest report says it licensed worldwide development and commercialization rights to Servier, which will lead the program.

Who Do They Compete With?

Competes with Janssen Biotech, Merck, Daiichi Sankyo, AstraZeneca, Summit Therapeutics, Akeso, Taiho Oncology, Bridge Biotherapeutics, J Ints Bio, Boehringer Ingelheim, ArriVent Biopharma, Shanghai Allist Pharmaceuticals, ORIC Pharmaceuticals, Cullinan Therapeutics, BlossomHill Therapeutics, Wayshine Biopharm International, Lilly Loxo Oncology, Verastem, Relay Therapeutics, and Incyte

Comments